According to our recent payer coverage analysis for rheumatoid arthritis (RA) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for RA treatments shows that about 73% of the covered lives under the commercial formularies are covered with utilization management restrictions.
Trends: With more biosimilars coming to market to compete against some of the older biologic-based drugs, an industry expert suggests that the RA market will see more competition. Via AIS Health.